These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31920314)

  • 1. Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2).
    Wu G; Gan R; Li Z; Xu L; Tang X; Wei Y; Hu Y; Cui H; Li H; Tang Y; Hui L; Liu X; Li C; Wang J; Zhang T
    Neuropsychiatr Dis Treat; 2019; 15():3541-3548. PubMed ID: 31920314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).
    Zhang T; Xu L; Tang X; Wei Y; Hu Q; Hu Y; Cui H; Tang Y; Hui L; Li C; Cao L; Lu Z; Wang J
    Aust N Z J Psychiatry; 2020 Jul; 54(7):696-706. PubMed ID: 32436725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
    Zhang T; Wang J; Xu L; Wei Y; Tang X; Hu Y; Cui H; Tang Y; Li C; Ling Z; Wang J
    Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):591-602. PubMed ID: 34536114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic Exposure in Clinical High Risk of Psychosis: Empirical Insights From a Large Cohort Study.
    Zeng J; Raballo A; Gan R; Wu G; Wei Y; Xu L; Tang X; Hu Y; Tang Y; Chen T; Li C; Wang J; Zhang T
    J Clin Psychiatry; 2022 Mar; 83(3):. PubMed ID: 35324095
    [No Abstract]   [Full Text] [Related]  

  • 5. Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion.
    Zhang TH; Li HJ; Woodberry KA; Xu LH; Tang YY; Guo Q; Cui HR; Liu XH; Chow A; Li CB; Jiang KD; Xiao ZP; Seidman LJ; Wang JJ
    Epidemiol Psychiatr Sci; 2017 Jun; 26(3):287-298. PubMed ID: 27056022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care.
    Fusar-Poli P; De Micheli A; Signorini L; Baldwin H; Salazar de Pablo G; McGuire P
    EClinicalMedicine; 2020 Nov; 28():100578. PubMed ID: 33294806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of conversion rates, clinical profiles and predictors of outcomes in two independent samples of individuals at clinical high risk for psychosis in China.
    Li H; Zhang T; Xu L; Tang Y; Cui H; Wei Y; Tang X; Woodberry KA; Shapiro DI; Li C; Seidman LJ; Wang J
    Schizophr Res; 2018 Jul; 197():509-515. PubMed ID: 29287626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Untreated Prodromal Psychosis and Cognitive Impairments.
    Zhang T; Cui H; Wei Y; Tang X; Xu L; Hu Y; Tang Y; Liu H; Wang Z; Chen T; Li C; Wang J
    JAMA Netw Open; 2024 Jan; 7(1):e2353426. PubMed ID: 38277145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision.
    Zhang T; Raballo A; Zeng J; Gan R; Wu G; Wei Y; Xu L; Tang X; Hu Y; Tang Y; Liu H; Chen T; Li C; Wang J
    Schizophrenia (Heidelb); 2022 May; 8(1):48. PubMed ID: 35853891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
    Pelizza L; Leuci E; Quattrone E; Azzali S; Paulillo G; Pupo S; Poletti M; Raballo A; Pellegrini P; Menchetti M
    Early Interv Psychiatry; 2024 Feb; 18(2):71-81. PubMed ID: 37194411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis.
    Raballo A; Poletti M; Preti A
    JAMA Psychiatry; 2024 Jul; 81(7):727-730. PubMed ID: 38506802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing risk of psychosis by sulforaphane study protocol for a randomized, double-blind, placebo-controlled, clinical multi-centre trial.
    Li Z; Zhang T; Xu L; Wei Y; Tang Y; Hu Q; Liu X; Li X; Davis J; Smith R; Jin H; Wang J
    Early Interv Psychiatry; 2021 Jun; 15(3):585-594. PubMed ID: 32436318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Combined Treatment Approach "Robin" (Standardized Manual and Smartphone App) for Adolescents at Clinical High Risk for Psychosis.
    Traber-Walker N; Gerstenberg M; Metzler S; Joris MR; Karr M; Studer N; Zulauf Logoz M; Roth A; Rössler W; Walitza S; Franscini M
    Front Psychiatry; 2019; 10():384. PubMed ID: 31244692
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.
    Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR
    Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: findings from ShangHai At Risk for Psychosis (SHARP) program.
    Zhang T; Xu L; Li H; Woodberry KA; Kline ER; Jiang J; Cui H; Tang Y; Tang X; Wei Y; Hui L; Lu Z; Cao L; Li C; Niznikiewicz MA; Shenton ME; Keshavan MS; Stone WS; Wang J
    Psychol Med; 2021 Mar; 51(4):653-660. PubMed ID: 31839016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis.
    Raballo A; Poletti M; Preti A
    Psychol Med; 2023 Oct; 53(14):6417-6423. PubMed ID: 37609894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator.
    Zhang T; Xu L; Li H; Cui H; Tang Y; Wei Y; Tang X; Hu Y; Hui L; Li C; Niznikiewicz MA; Shenton ME; Keshavan MS; Stone WS; Wang J
    Psychol Med; 2021 Feb; ():1-10. PubMed ID: 33593473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
    Seidman LJ; Giuliano AJ; Meyer EC; Addington J; Cadenhead KS; Cannon TD; McGlashan TH; Perkins DO; Tsuang MT; Walker EF; Woods SW; Bearden CE; Christensen BK; Hawkins K; Heaton R; Keefe RS; Heinssen R; Cornblatt BA;
    Arch Gen Psychiatry; 2010 Jun; 67(6):578-88. PubMed ID: 20530007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis.
    Hagler MA; Ferrara M; Yoviene Sykes LA; Li F; Addington J; Bearden CE; Cadenhead KS; Cannon TD; Cornblatt BA; Perkins DO; Mathalon DH; Seidman LJ; Tsuang MT; Walker EF; Powers AR; Allen AR; Srihari VH; Woods SW
    Schizophr Res; 2023 May; 255():239-245. PubMed ID: 37028205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.